---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-004707"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-06-10T20:15:25+00:00"
generated_at: "2026-06-10T20:23:48.288121+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort

## Summary
- Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.
- Cash $5.0M at March 31; subsequent $1.85M raised via ATM program.
- Australian oncology study advanced to Cohort 3; first patient treated in final dosing cohort.
- Patents issued in US and Europe for Hemopurifier in long COVID/coronavirus, extending protection to 2040s.
- Preclinical studies for rheumatoid arthritis and chronic kidney disease underway.

## SEC filing metadata
- accession: 0001683168-26-004707
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-06-10T20:15:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/0001683168-26-004707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-004707
- JSON: https://secwatch.observer/filing/0001683168-26-004707.json
- Plain text: https://secwatch.observer/filing/0001683168-26-004707.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported financial results for the fiscal year ended March 31, 2026.
  - Period: the fiscal year ended March 31, 2026
  - Result: reported results
  source text: Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/0001683168-26-004707-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.